Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor use and sexual dysfunction: a pharmacovigilance analysis - PubMed
8 hours ago
- #antidepressants
- #sexual dysfunction
- #pharmacovigilance
- SSRIs and SNRIs, while effective antidepressants, carry a significant risk of sexual dysfunction.
- A pharmacovigilance analysis using the FAERS database assessed associations via reporting odds ratios and information components.
- All studied antidepressants (sertraline, citalopram/escitalopram, paroxetine, fluoxetine, venlafaxine, duloxetine) were linked to sexual dysfunction, but symptom profiles varied.
- Sertraline showed the widest range of sexual dysfunction manifestations, whereas duloxetine had a more limited profile.
- The study provides real-world evidence to help clinicians select antidepressants, identify high-risk patients, and improve compliance and quality of life.
- Strengths include large-scale data from FAERS, but limitations include underreporting and lack of clinical context, limiting causal inference.